Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 85.0/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 59.8; sample size: 80.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 44.1; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 58.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.6/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 48.1; sample size: 50.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 60.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 37.5; sample size: 100.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.3/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 84.2; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.2/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 66.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.2/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 26.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 67.7; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 70.1; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.0/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 50.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 84.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 49.8; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.9/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 72.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 54.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 73.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.6/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 38.0; sample size: 90.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 50.2; sample size: 80.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.5/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 80.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 83.5/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 47.5; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
